Ironwood Pharmaceuticals raised its full-year LINZESS revenue guidance above $1 billion and reported debt below 1.0 times EBITDA Thursday, signaling a turnaround driven by the rebound of its flagship constipation treatment.
The company, which trades at $3.97 — down from a 52-week high of $5.78 but up 254% over the past year — revealed mid-year guidance for revenue of $460 million to $485 million and adjusted EBITDA above $310 million during its presentation at the Wells Fargo 21st Annual Healthcare Conference.
Chief Executive Officer Tom McCourt and Chief Commercial Officer Tammi Gaskins highlighted the recovery in LINZESS, which generates net sales swings of $300 million to $350 million and now serves nearly 5 million unique patients for irritable bowel syndrome with constipation and chronic idiopathic constipation. Demand growth tracked at 5% through June, with mid-single-digit full-year growth expected.
Medicare Part D remains the largest segment of LINZESS's book of business, followed by commercial coverage and Medicaid. Ironwood maintained 100% Medicare coverage for the drug and strategically reduced its list price to eliminate inflationary rebates across all channels.
On the balance sheet, Ironwood paid off a $200 million convertible debt instrument, bringing leverage below 1.0 times EBITDA and ending the year in that range. The company's free cash flow yield stands at 28%, its P/E ratio is 5.07, and it holds a Piotroski score of 9 out of 9.
Revenue grew 26% over the last twelve months, with guidance tracking toward about 30% year-over-year growth.
Looking further ahead, CEO McCourt pointed to apraglutide, a once-weekly GLP-2 receptor agonist for short bowel syndrome with intestinal failure. Peak sales are estimated to exceed $700 million even after generic teduglutide — the active ingredient in GATTEX, which Ironwood competes against — arrives in the 2026 to 2027 window.
FDA requested a confirmatory trial for apraglutide following a positive Phase 3 STARS study because a vial change and unclear patient directions caused some patients to receive 3.5 milligrams instead of the intended 5 milligrams. The package was redesigned and human factors studies completed. The new confirmatory trial features a 24-week primary endpoint using an aggregate patient population and targets an NDA filing by 2029.
About 20% of apraglutide patients in trials achieved enteral autonomy — no longer needing parenteral support. The U.S. eligible population is estimated at roughly 8,000 patients, of whom only 1,500 to 2,000 are currently on GATTEX. About 90% of patients remained on therapy in the STARS Extend long-term follow-up study.
GATTEX, approved in 2012, sees a discontinuation rate of approximately 50% in the first 12 months, leaving a significant addressable market for apraglutide.
Cipla has publicly indicated it may launch a generic teduglutide in the 2026 to 2027 period, adding competitive pressure on GATTEX's revenue stream that further underscores the strategic importance of apraglutide to Ironwood's future growth.
